Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon National Health Strategy-Vision 2030



Lebanon National Health Strategy – Vision 2030- Two Year Review
Lebanon National Health Strategy – Vision 2030- One Year Review

Introduction

In January 2023, the Ministry of Public Health (MoPH) launched its National Health Strategy: Vision 2030. Vision 2030 set out the framework for a sustained and modernized recovery of the health sector and intended to address the challenges of leading a burned-out health system. Through this strategy, and under the leadership of the MoPH, the different partners of the health sector joined efforts to respond to the escalating unmet health needs and participate in building a stronger, more resilient health system.

Over the past year, the National Health Strategy has made significant strides in enhancing the overall well-being of the population. The multifaceted approach has addressed key issues such as human resources shortage, challenged healthcare accessibility, and the massive gaps in health financing. Despite the multiple predicaments in the country, including the ongoing war and hostilities; the economic collapse and financial meltdown; the extended refugee crisis with its associated increased demand for scarce health resources; and disease outbreaks such as cholera; the health sector remained steady, and determined in achieving progress across the objectives outlined in the National Health Strategy. The National Health Strategy’s commitment to fostering advanced governance and financing mechanisms, investing in essential public health functions, strengthening primary healthcare, capacitating human resources, and embracing digital health technologies is expected to result in an advanced, more equitable, more inclusive, and more sustainable healthcare delivery.(Read More...)
 
Lebanon National Health Strategy: Vision 2030
 
Executive Summary

Lebanon is passing through one of the most severe and complex crises in its recent history, caused by the interplay of political turbulence, socioeconomic meltdown, and the lingering COVID-19 pandemic. Regionally, conflict and instability continue to result in the influx of refugees, which constitute now around one third of the Lebanese population.

The intertwined crises Lebanon has been suffering from unmasked the effects of pre-existing health system inefficiencies, including the predominance of tertiary care over preventive and primary care; a weakened public health sector; a pluralistic financing system; and a supply-induced demand with unsustainable and unrealistic expectations. The synergistic effects of these crises amplified the malfunctioning of a disrupted health system, rendering a system notorious for its resilience at the verge of a breakdown. As a result, the ability to respond to the increased needs of a growing population was deterred. Equitable access to care was exceptionally difficult for people with vulnerabilities. Worsening in health outcomes was noted at many fronts: life expectancy, maternal mortality, under 5 mortality, and childhood vaccination. Previously forgotten diseases such as diphtheria, tetanus, and most recently cholera re-emerged, and the health gains of previous years have started to fade away.

The multifaceted crisis has also severely impacted access to and utilization of healthcare services. The percentage of households with difficulty accessing health care rose from 25% to 36% within around 4 months during the year 2020. Hospitalizations, particularly for surgeries, diminished by 30% in 2021, and the average monthly hospitalization days decreased by 25%. The cost of treatments, medical consultations, or transportation to health facilities have become prohibitive to many, resulting in delayed presentation of patients for medical attention, who at many times presented with decompensated or non-salvageable conditions. Duly, challenged access to specialized healthcare was coupled with an exponential increased demand on the services provided by the Primary Health Care Network. With crisis, an opportunity has emerged for repositioning primary health care as a gateway for affordable, quality promotive, preventive, and primary health services, and for moving closer towards achieving Universal Health Coverage.

The recent drain of human resources particularly those with high competencies and specialization has become an increasing concern, with more than 20% of nurses and around 40% of doctors having already left the country. Additionally, the layoffs, salary cuts and closures of pharmacies and the reduced activities of hospitals which accompanied the economic crisis, deleteriously affected the healthcare workforce. This shortage in qualified human resources endangered the quality and availability of health care services.

The pharmaceutical sector was also hit hard by the crisis. In 2020, the government’s policy of relying on external sources for medications and medical supplies, coupled the economic crisis, led to drops in imports, resulting in severe market shortages. This has paved the way to hoarding, smuggling, black market practices, and the entry of illegal, low-quality drugs and supplies into the country.(Read More...)


ِAnnexes:
    5
ATC Name B/G Ingredients Dosage Form Price
L01FA01 RUXIENCE BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 13,157,756 L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg 500mg/50ml Injectable concentrated solution 45,258,360 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 64,401,569 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 111,983,163 L.L
L01FA01 RUXIENCE BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 59,148,151 L.L
L03AB07 REBIF BioTech Interferon beta-1a - 44mcg/0.5ml 12MIU Injectable solution 79,337,698 L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution 15,147,973 L.L
L03AX16 REVIXIL 20 G Plerixafor - 20mg/ml 20mg/ml Injectable solution 248,280,900 L.L
L04AA10 RAPAMUNE B Sirolimus - 1mg 1mg Tablet 12,907,489 L.L
L04AA44 RINVOQ B Upadacitinib - 15mg 15mg Tablet, prolonged release 45,469,094 L.L
L04AB02 REMICADE BioTech Infliximab - 100mg 100mg Injectable concentrated powder for solution 30,111,023 L.L
L04AB02 REMSIMA BioTech Infliximab - 100mg 100mg Injectable concentrated powder for solution 24,943,134 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 91,457,321 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 179,063,666 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 52,597,003 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 179,063,666 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 91,457,321 L.L
L04AB02 REMSIMA SC BioTech Infliximab - 120mg/ml 120mg/ml Injectable solution 52,597,003 L.L
L04AX04 REVLIMID B Lenalidomide - 5mg 5mg Capsule 105,106,076 L.L
L04AX04 REVLIMID B Lenalidomide - 10mg 10mg Capsule 110,200,672 L.L
L04AX04 REVLIMID B Lenalidomide - 15mg 15mg Capsule 116,241,703 L.L
L04AX04 REVLIMID B Lenalidomide - 25mg 25mg Capsule 127,865,045 L.L
M01AB05 REMETHAN G Diclofenac sodium - 50mg 50mg Tablet 196,201 L.L
M01AB05 ROFENAC D G Diclofenac free acid - 50mg 50mg Tablet, dispersible 408,528 L.L
M01AB05 RAPIDUS G Diclofenac potassium - 50mg 50mg Tablet, coated 287,582 L.L
M01AC02 REUTENOX G Tenoxicam - 20mg 20mg Tablet, coated 576,508 L.L
M01AE51 RELI-FLU G Ibuprofen - 200mg, Pseudoephedrine HCl - 30mg Tablet, film coated 139,504 L.L
M01AH01 REVCOX G Celecoxib - 200mg 200mg Capsule 506,629 L.L
M01AH01 REVCOX G Celecoxib - 200mg 200mg Capsule 506,629 L.L
M02AA31 ROXONIN B Loxoprofen (Sodium) - 60mg 60mg Tablet 788,836 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025